Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Pharmacopeia And Acadia Cut Workforce
August 11, 2008
| A version of this story appeared in
Volume 86, Issue 32
Two drug discovery and development companies have revealed restructurings and workforce reductions timed to second-quarter earnings announcements. Acadia Pharmaceuticals will focus on its Phase III trials of pimavanserin for Parkinson's disease psychosis and two compounds funded by partner Allergan. It plans to reduce its workforce by 50%, to 65 employees. Pharmacopeia will terminate 40% of its workforce, in addition to a 15% reduction in May 2008. The company, which had 169 employees at the end of 2007, plans to begin Phase II trials on PS433540, a small-molecule drug for diabetic nephropathy.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter